Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies

Anti-Cancer Agents in Medicinal Chemistry, 13(10): 1552-1564.

Author(s): Asif Khurshid Qazi, Aashiq Hussain, Abid Hamid, Yasrib Qurishi, Rabiya Majeed, Mudassier Ahmad, Rauf Ahmad Najar, Javeed Ahmad Bhat, Shashank Kumar Singh, Mohmmad Afzal Zargar, Shakir Ali and Ajit Kumar Saxena.

Affiliation: Cancer Pharmacology Division, Indian Institute of Integrative Medicine, Medicine (Council of Scientific and Industrial Research) Canal Road, Jammu-Tawi 180001 India.


Cancer is a diverse class of diseases which differ widely in their cause and biology. The aberrant behavior of cancer reflects up regulation of certain oncogenic signaling pathways that promote proliferation, inhibit apoptosis, and enable the cancer to spread and evoke angiogenesis. Phosphoinositide-3-kinase(PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway controls various biological processes that are important for normal functioning of the cell via cell cycle progression, survival, migration, transcription, translation and metabolism. However, PI3K signaling pathway is dysregulated almost in all cancers which is due to the amplification and genetic mutation of PI3K gene, encoding catalytic and regulatory subunit of PI3K isoforms. The current review focuses on the structural features of various PI3K isoforms including Akt and mTOR and their inhibition using specific small molecule inhibitors in an attempt to achieve an attractive target for cancer prevention and chemotherapy.


Anticancer target, cancer, inhibitors, PI3K-Akt-mTOR, Signaling, therapy, translation.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 13
Issue Number: 10
First Page: 1552
Last Page: 1564
Page Count: 13
DOI: 10.2174/1871520613666131125123241
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science